Guideline Updates

NCCN B-Cell Lymphomas Guideline Features Therapy Updates in Follicular Lymphoma, DLBCL

July 13, 2020

The National Comprehensive Cancer Network (NCCN) released an update to its guideline for B-cell lymphomas.

In the section for follicular lymphoma with histologic transformation to diffuse large B-cell lymphoma (DLBCL) after multiple lines of prior therapy, selinexor was added as a category 2A recommendation only after at least two lines of systemic therapy.

Under the suggested treatment regimens for follicular lymphoma in the second-line and subsequent therapy setting, tazemetostat was added as a category 2A recommendation for two indications: EZH2 mutation-positive relapsed/refractory disease after two prior therapies, and EZH2 wild type relapsed/refractory disease in patients who do not have any satisfactory alternative treatment options.

Lastly, in the section for DLBCL, a new therapy is listed for third-line and subsequent therapy – including patients with disease progression after transplant or CAR T-cell therapy. Selinexor is now recommended as a category 2A recommendation only after at least two lines of systemic therapy.—Zachary Bessette